CTLA4 and neoplasm: In a mouse model of pancreatic cancer, treatment with anti-PD1, and anti-CTLA4 antibodies in combination with TAM depletion by a CSF1 receptor antagonist (PLX3397) blocks tumor expansion more efficiently compared with a single treatment with anti-PD1/anti-CTLA4 or PLX3397 (118).